Discovery of OPEVESOSTAT, Novel, First-In-Class CYP11A1 Inhibitor - with Potent and Selective Anti-Tumor Activity in mCRPC

A novel CYP11A1 inhibitor blocking steroid hormone biosynthesis

Riikka -- Oksala, PhD

Orion Pharma

Role of HSD3B1 in endocrine therapy resistance in cancer

Nima -- Sharifi, MD

University of Miami

Chair

Richard Santen, MD

University of Virginia

Chair

Julie -- Pollock, PhD

University of Richmond

HSD11B1 inhibition reducing toxicities of glucocorticoids

David A Katz, PhD

Sparrow Pharmaceuticals